Juul Labs, the big e-cigarette maker that is embroiled in controversy involving the rising underage use of vaping products, announced Wednesday that its chief executive officer is stepping down and will be succeeded by a top official from Altria, a part-owner of Juul.
Juul also said it will not lobby against a proposed ban, announced recently by President Trump, on most flavored vaping products. It said it is suspending all broadcast, print and digital product advertising in the United States.
Kevin Burns, Juul’s chief executive officer, is being succeeded by K.C. Crosthwaite, Altria’s senior vice president for chief strategy and growth. Crosthwaite oversaw “commercial and regulatory efforts” related to the launch in the United States of IQOS, a “heat-not-burn” alternative to cigarettes, Juul said in a news release. IQOS is made by Philip Morris International and marketed in the United States by Altria.
Altria owns a 35 percent stake in Juul.
FDA blasts Juul for illegally marketing e-cigarettes as less harmful than regular cigarettes
Juul also said it will end its “Make the Switch” campaign that FDA officials had criticized for implying that its e-cigarettes are safer than regular cigarettes. The agency has to give companies specific authorization to make such a claim.
The staff shake-up was announced by Burns and Juul co-founders James Monsees and Adam Bowen. [Read More @ The Washington Post]
Your email address will not be published. Required fields are marked *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Comment *
Notify me of follow-up comments by email.
Notify me of new posts by email.
Δ
POSaBIT, the cannabis point-of-sale (POS) and payments software company, this morning announced its planned acquisition of MJ Platform (MJ Freeway), Leaf Data Systems, and Ample Organics from embattled software company…
New York marijuana regulators on Wednesday approved dozens of conditional adult-use dispensary licenses in a session during which members also discussed adopting bylaws for how the board runs meetings and makes decisions.…
By Griffin Thorne, Attorney at Harris Bricken Since the passage of the 2018 Farm Bill, the hemp CBD industry has been eagerly awaiting FDA CBD regulations. In that time, FDA…
The US Food and Drug Administration has finalized a 2020 draft guidance outlining how sponsors and investigators can conduct clinical trials for certain drugs containing cannabis or cannabis-derived compounds without…